Will natural products remain an important source of drug research for the future?

Current Opinion in Biotechnology

Volumn 8, Issue 6, 1997, Pages 708-712

  Nisbet, Louis J ^a   Moore, Michael ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL PRODUCT;

DATA BASE; DRUG DEVELOPMENT; DRUG RESEARCH; DRUG SYNTHESIS; GENOME; MOLECULAR GENETICS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

EID: 0030707561     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(97)80124-3     Document Type: Article

References (32)

1. Suffness M. Taxol: from discovery to therapeutic use. Ann Rep Med Chem. 28:1993;305-314.
2. Joel SP. Taxol and taxotere: from yew tree to tumour cell. Chem Ind. 1994;172-175.
3. Fabre JL, Locci-Tonelli D, Spiridonidis CH. Docetaxel. Drugs Future. 20:1995;464-471.
4. Cheng X-M. To market, to market - 1995. Ann Rep Med Chem. 31:1996;337-355.
5. Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud P-Y, Vrignaud P, Bissery M-C, Veith JM, Pera P, Bernacki RJ. Syntheses and structure activity relationships of the second generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J Med Chem. 39:1996;3889-3896.
6. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55:1995;2325-2333.
7. Slichenmyer WC, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents (review). J Nat Cancer Inst. 85:1993;271-291.
8. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition. DNA damage, and cytotoxity of camptothecin derivatives presently in clinical trials. J Nat Cancer Inst. 86:1994;836-842.
9. Dale IL, Luscombe M, Holmes JA, Martin K, Tuffley W, Ryder H, Pretswell I, Ashworth P, Mistry P, Bevan P, Twentyman PR. Reversal of p-glycoprotein (P-gp)-mediated multidrug resistance (MDR) in vitro and in vivo by XR9051, a novel diketopiperazine (DKP) derivative. Ann Oncol. 7:1996;123. (suppl 1).
10. Holmes JA, Luscombe M, Dale IL, Brocchini S, Bryans JS, Latham CJ, Moore M, Twentyman PR. Identification and characterization of a novel diketopiperazine as a modulator of P-glycoprotein-mediated multidrug resistance. Anti-Cancer Drugs. 5:1994;40-41. (suppl 1).
11. Pettit GR. Marine animal and terrestrial plant anticancer constituents. Pure Appl Chem. 66:1994;2271-2281.
12. Cragg GM, Boyd MR, Christini MA, Kneller R, Mays TD, Mazan KD, Newman DJ, Sausville EA. Screening of natural products of plant, microbial and marine origin: The NCI experience. of special interest Wrigley SK, Hayes MA, Chrystal EJ, Thomas R. Phytochemical Diversity: A Source of New Industrial Products. 1997;1-29 Royal Society of Chemistry, Cambridge (UK), A review of the development of NCIs strategy to support the discovery of natural products with the potential to treat cancer. Important successes include taxol and the camptothecin derivatives.
13. De Vita VT Jr, Hellman S, Rosenberg SA. edn 5 Cancer: Principles and Practice of Oncology. 1985;Lippincott-Raven, Philadelphia.
14. Perico N, Remuzzi G. New antirejection drugs. Exp Opin Ther Pat. 6:1996;871-891.
15. Cheng X-M. To market, to market - 1993. Ann Rep Med Chem. 29:1994;331-354.
16. Bryans J, Charlton P, Chicarelli-Robinson I, Collins M, Faint R, Latham C, Shaw I, Trew S. Inhibition of plasminogen activator inhibitor-1 activity by two diketopiperazines, XR330 and XR 334 produced by Streptomyces sp. J Antibiotics. 49:1996;1014-1021.
17. Charlton P, Faint R, Bent F, Bryans J, Chicarelli-Robinson I, Mackie I, Machin S, Bevan P. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost. 75:1996;808-815.
18. Charlton P, Faint R, Barnes C, Bent F, Folkes A, Templeton D, Mackie I, Machin S, Bevan P. XR 5118, a novel modulator of plasminogen activator inhibitor-1 (PAI-1), increases endogenous tPA activity in the rat. Fibrinolysis Proteolysis. 11:1997;51-56.
19. Moore M. Attack as the best form of defense: natural products in the forefront of contemporary drug research. of special interest J Biomol Screen. 1:1996;19-21 Summarises the advantages of natural products as a source of chemical diversity for drug discovery.
20. Chicarelli-Robinson MI. Third IBC International Conference on Natural Products in Drug Discovery. March 1997;. Coronado, California.
21. Tong G, Nielsen J. A convergent solid-phase synthesis of actinomycin analogues - towards implementation of double-combinatorial chemistry. of special interest Bioorg Med Chem. 4:1996;693-698 This is one of the first papers to describe the combinatorial generation of sub-libraries of natural products.
22. Khosla C, Zawada RJX. Generation of polyketide libraries via combinatorial biosynthesis. of outstanding interest Trends Biotechnol. 14:1996;335-341 Reviews the potential for genetic manipulation of polyketide synthases to synthesis 'unnatural' polyketide natural products.
23. McDaniel R, Ebert-Khosla S, Hopwood DA, Khosla C. Rational design of aromatic polyketide natural products by recombinant assembly of enzymatic subunits. Nature. 375:1995;549-554.
24. Rouhi M. DNA technology yields diverse drug leads. Chem Eng News. 9:1995;2.
25. Lee MD, Durr FE, Hinmam LM, Hamann PR, Ellestad GA. The calicheamicans. Adv Med Chem. 2:1993;31-66.
26. Konishi M, Ohkuma H, Tsuno T, Oki T, VanDuyne GD, Clardy J. Crystal and molecular structure of dynemicin A: a novel 1,5-Diyn-3-ene antitumor antibiotic. J Am Chem Soc. 112:1990;3715-3716.
27. Danishefsky SJ, Shair MD. Observations in the chemistry and biology of cyclic enediyne antibiotics: total syntheses of calicheamicin, and dynemicin A. of special interest J Org Chem. 61:1996;16-44 Reviews notable achievements in the synthesis of these complex natural products.
28. Nicolaou KC, Dai W-M, Tsay S-C, Estevez VA, Wrasidlo W. Designed enediynes: a new class of DNA-cleaving molecules with potent and selective anticancer activity. Science. 256:1992;1172-1178.
29. Ho SN, Boyer SH, Schreiber SL, Danishefsky SJ, Crabtree GR. Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: a paradigm for the development of transcriptional antagonists. Proc Natl Acad Sci USA. 91:1994;9203-9207.
30. Clough JM. The strobilurins, oudemansins, and myxothiazols, fungicidal derivatives of β-methoxyacrylic acid. Nat Prod Rep. 10:1993;565-574.
31. Miller A. The strobilurin race heats up. Chem Ind. 1997;7.
32. Kastelic T, Schnyder J, Leutwiles A, Traber R, Streit B, Niggli H, MacKenzie A, Cheneval D. Induction of rapid IL-Iβ mRNA degradation in THP-1 cells mediated through the AU rich region in the 3′ UTR by a radical analogue. Cytokine. 8:1996;751-761.